But is Rybrevant deep enough, and does ficerafusp use the right pivotal dose?
ApexOnco Front Page
Recent articles
2026’s first big oncology buyout is here.
Leaked data ahead of the ESMO late breaker show a progression-free survival benefit that looks practice-changing.
The latest first-in-human trial entrants include several novel mechanisms, a PSMA radioconjugate and a new pan-KRAS challenger.
Phase 1 data suggest the group’s KRAS G12C inhibitor has activity, crucially in KRAS-experienced patients.
Initial data on Amgen’s AMG 193 give some Tango investors a headache.
The company’s FGFR2 inhibitor shows potential beyond cholangiocarcinoma, but the markets aren’t buying it.
Data on PMV’s p53 reactivator prompt a 26% selloff before their presentation, and 48% afterwards.